Wire · operational-macro
Radiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
PharmaLogic has acquired Lantheus' contract development and manufacturing organization (CDMO) business and its manufacturing facility in Springfield, New Jersey, expanding its radiopharmaceutical production capacity in the U.S. This move strengthens PharmaLogic's global radioligand therapy capabilities and runs alongside Curium's ongoing $8 billion acquisition of Lantheus.
This Wire brief sits within Fusion42's coverage of Health: Biotech.
◆ ◆ The Wire takeaway
You must factor in a growing supply bottleneck easing as PharmaLogic scales U.S. radiopharmaceutical capacity by absorbing Lantheus' CDMO and plant. This sets a clearer path for expanding therapeutic radioligand availability and challenges peers to match their broader service reach.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics